Primary mediastinal large B-cell lymphoma with sclerosis

A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy

P. L. Zinzani, M. Martelli, A. De Renzo, A. Zaccaria, E. Pavone, M. Bocchia, B. Falini, M. Gobbi, F. Gherlinzoni, M. Bendandi, V. Stefoni, M. Tani, S. Tura

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background and Objectives. Primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis has recently been recognized as a specific clinical and pathologic entity for which the best therapeutic approach seems to be a combination of chemotherapy and radiotherapy. Design and Methods. Between 1989 and 1998, 89 previously unheated patients with PMLBCL with sclerosis were treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and mediastinal radiation therapy. The response evaluations were examined after chemotherapy and at the end of radiotherapy. Results. Twenty-three (26%) patients achieved a complete response (CR) and 59 (66%) obtained a partial response (PR) after the MACOP-B regimen. After radiation therapy, 55/59 (93%) of the patients in PR achieved CR. The CR rate at the end of the treatment was 88% (78/89). Only 7 (8%) patients were non-responders. Among the 78 patients who obtained a CR them were 7 (9%) relapses in a median follow-up of 5 months (all relapses occurred within 9 months); the other 71 patients are currently in continuous CR with a median follow-up of 45 months (range, 4-110 months). Projected overall survival was 86% at 9 years; the relapse-free survival curve of the 78 patients who achieved CR was 91% at 9 years. Interpretation and Conclusions. In patients with PMLBCL with sclerosis, combined modality treatment using the MACOP-B chemotherapy regimen and radiation therapy induces a good remission rate with the patients having a greater than 90% chance of surviving disease-free at 9 years. Radiotherapy often plays a pivotal role in obtaining CR status.

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalHaematologica
Volume86
Issue number2
Publication statusPublished - 2001

Fingerprint

Sclerosis
B-Cell Lymphoma
Radiotherapy
Drug Therapy
Recurrence
Clinical Studies
Survival
Combination Drug Therapy
Therapeutics

Keywords

  • MACOP-B regimen
  • PMLBCL with sclerosis
  • Radiation therapy
  • Relapse-free survival

ASJC Scopus subject areas

  • Hematology

Cite this

Zinzani, P. L., Martelli, M., De Renzo, A., Zaccaria, A., Pavone, E., Bocchia, M., ... Tura, S. (2001). Primary mediastinal large B-cell lymphoma with sclerosis: A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica, 86(2), 187-191.

Primary mediastinal large B-cell lymphoma with sclerosis : A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. / Zinzani, P. L.; Martelli, M.; De Renzo, A.; Zaccaria, A.; Pavone, E.; Bocchia, M.; Falini, B.; Gobbi, M.; Gherlinzoni, F.; Bendandi, M.; Stefoni, V.; Tani, M.; Tura, S.

In: Haematologica, Vol. 86, No. 2, 2001, p. 187-191.

Research output: Contribution to journalArticle

Zinzani, PL, Martelli, M, De Renzo, A, Zaccaria, A, Pavone, E, Bocchia, M, Falini, B, Gobbi, M, Gherlinzoni, F, Bendandi, M, Stefoni, V, Tani, M & Tura, S 2001, 'Primary mediastinal large B-cell lymphoma with sclerosis: A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy', Haematologica, vol. 86, no. 2, pp. 187-191.
Zinzani, P. L. ; Martelli, M. ; De Renzo, A. ; Zaccaria, A. ; Pavone, E. ; Bocchia, M. ; Falini, B. ; Gobbi, M. ; Gherlinzoni, F. ; Bendandi, M. ; Stefoni, V. ; Tani, M. ; Tura, S. / Primary mediastinal large B-cell lymphoma with sclerosis : A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. In: Haematologica. 2001 ; Vol. 86, No. 2. pp. 187-191.
@article{086e5d20b3324081859db8bf97d2c220,
title = "Primary mediastinal large B-cell lymphoma with sclerosis: A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy",
abstract = "Background and Objectives. Primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis has recently been recognized as a specific clinical and pathologic entity for which the best therapeutic approach seems to be a combination of chemotherapy and radiotherapy. Design and Methods. Between 1989 and 1998, 89 previously unheated patients with PMLBCL with sclerosis were treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and mediastinal radiation therapy. The response evaluations were examined after chemotherapy and at the end of radiotherapy. Results. Twenty-three (26{\%}) patients achieved a complete response (CR) and 59 (66{\%}) obtained a partial response (PR) after the MACOP-B regimen. After radiation therapy, 55/59 (93{\%}) of the patients in PR achieved CR. The CR rate at the end of the treatment was 88{\%} (78/89). Only 7 (8{\%}) patients were non-responders. Among the 78 patients who obtained a CR them were 7 (9{\%}) relapses in a median follow-up of 5 months (all relapses occurred within 9 months); the other 71 patients are currently in continuous CR with a median follow-up of 45 months (range, 4-110 months). Projected overall survival was 86{\%} at 9 years; the relapse-free survival curve of the 78 patients who achieved CR was 91{\%} at 9 years. Interpretation and Conclusions. In patients with PMLBCL with sclerosis, combined modality treatment using the MACOP-B chemotherapy regimen and radiation therapy induces a good remission rate with the patients having a greater than 90{\%} chance of surviving disease-free at 9 years. Radiotherapy often plays a pivotal role in obtaining CR status.",
keywords = "MACOP-B regimen, PMLBCL with sclerosis, Radiation therapy, Relapse-free survival",
author = "Zinzani, {P. L.} and M. Martelli and {De Renzo}, A. and A. Zaccaria and E. Pavone and M. Bocchia and B. Falini and M. Gobbi and F. Gherlinzoni and M. Bendandi and V. Stefoni and M. Tani and S. Tura",
year = "2001",
language = "English",
volume = "86",
pages = "187--191",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Primary mediastinal large B-cell lymphoma with sclerosis

T2 - A clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy

AU - Zinzani, P. L.

AU - Martelli, M.

AU - De Renzo, A.

AU - Zaccaria, A.

AU - Pavone, E.

AU - Bocchia, M.

AU - Falini, B.

AU - Gobbi, M.

AU - Gherlinzoni, F.

AU - Bendandi, M.

AU - Stefoni, V.

AU - Tani, M.

AU - Tura, S.

PY - 2001

Y1 - 2001

N2 - Background and Objectives. Primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis has recently been recognized as a specific clinical and pathologic entity for which the best therapeutic approach seems to be a combination of chemotherapy and radiotherapy. Design and Methods. Between 1989 and 1998, 89 previously unheated patients with PMLBCL with sclerosis were treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and mediastinal radiation therapy. The response evaluations were examined after chemotherapy and at the end of radiotherapy. Results. Twenty-three (26%) patients achieved a complete response (CR) and 59 (66%) obtained a partial response (PR) after the MACOP-B regimen. After radiation therapy, 55/59 (93%) of the patients in PR achieved CR. The CR rate at the end of the treatment was 88% (78/89). Only 7 (8%) patients were non-responders. Among the 78 patients who obtained a CR them were 7 (9%) relapses in a median follow-up of 5 months (all relapses occurred within 9 months); the other 71 patients are currently in continuous CR with a median follow-up of 45 months (range, 4-110 months). Projected overall survival was 86% at 9 years; the relapse-free survival curve of the 78 patients who achieved CR was 91% at 9 years. Interpretation and Conclusions. In patients with PMLBCL with sclerosis, combined modality treatment using the MACOP-B chemotherapy regimen and radiation therapy induces a good remission rate with the patients having a greater than 90% chance of surviving disease-free at 9 years. Radiotherapy often plays a pivotal role in obtaining CR status.

AB - Background and Objectives. Primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis has recently been recognized as a specific clinical and pathologic entity for which the best therapeutic approach seems to be a combination of chemotherapy and radiotherapy. Design and Methods. Between 1989 and 1998, 89 previously unheated patients with PMLBCL with sclerosis were treated with a combination of a third-generation chemotherapy regimen (MACOP-B) and mediastinal radiation therapy. The response evaluations were examined after chemotherapy and at the end of radiotherapy. Results. Twenty-three (26%) patients achieved a complete response (CR) and 59 (66%) obtained a partial response (PR) after the MACOP-B regimen. After radiation therapy, 55/59 (93%) of the patients in PR achieved CR. The CR rate at the end of the treatment was 88% (78/89). Only 7 (8%) patients were non-responders. Among the 78 patients who obtained a CR them were 7 (9%) relapses in a median follow-up of 5 months (all relapses occurred within 9 months); the other 71 patients are currently in continuous CR with a median follow-up of 45 months (range, 4-110 months). Projected overall survival was 86% at 9 years; the relapse-free survival curve of the 78 patients who achieved CR was 91% at 9 years. Interpretation and Conclusions. In patients with PMLBCL with sclerosis, combined modality treatment using the MACOP-B chemotherapy regimen and radiation therapy induces a good remission rate with the patients having a greater than 90% chance of surviving disease-free at 9 years. Radiotherapy often plays a pivotal role in obtaining CR status.

KW - MACOP-B regimen

KW - PMLBCL with sclerosis

KW - Radiation therapy

KW - Relapse-free survival

UR - http://www.scopus.com/inward/record.url?scp=20244370498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244370498&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 187

EP - 191

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -